Samuel S. Coleman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samuel S. Coleman has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Afaf E.G. Osman
17Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, Utah
76 shared publications - Ahmad A. Tarhini
Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
76 shared publications - Aik Choon Tan
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA
76 shared publications - Alexandra P. Ikeguchi
The University of Texas MD Anderson Cancer Center 12 Houston, TX
76 shared publications - Carlos H. F. Chan
Department of Surgery, University of Iowa Hospitals and Clinics, Iowa, USA
76 shared publications - Caroline E. Wheeler
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
76 shared publications
Latest Publications
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
16 gene signatures where high Z-scores are associated with ICI responsiveness in this cohort (FDR < 0.05)
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
16 gene signatures where high Z-scores are associated with ICI responsiveness in this cohort (FDR < 0.05)
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Association of CIBERSORT cell types with the response to ICIs
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Association of CIBERSORT cell types with the response to ICIs
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Predictive values (AUROC) of the 16 gene signatures in the ORIEN cohort (IO_NOVA_Mel) and 22 other melanoma cohorts
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Predictive values (AUROC) of the 16 gene signatures in the ORIEN cohort (IO_NOVA_Mel) and 22 other melanoma cohorts
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Correlations between microbe abundances and MSigDB Hallmark gene sets average Z scores
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Correlations between microbe abundances and MSigDB Hallmark gene sets average Z scores
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Comparison with TCGA for microbes most significantly enriched in response groups
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Comparison with TCGA for microbes most significantly enriched in response groups
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Comparison of alternate machine learning methods
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Comparison of alternate machine learning methods
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Modeling results for gene expression differences between responders and non-responders
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Modeling results for gene expression differences between responders and non-responders
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Model performance of 31 published gene expression signatures for predicting immunotherapy treatment response
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Model performance of 31 published gene expression signatures for predicting immunotherapy treatment response
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Modeling results for the microbes enriched in the tumors responsive or not-responsive to immunotherapy
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Modeling results for the microbes enriched in the tumors responsive or not-responsive to immunotherapy
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
The list of published gene signatures compared between treatment responders and non-responders and to tumor microbe abundances.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
The list of published gene signatures compared between treatment responders and non-responders and to tumor microbe abundances.